{
  "$schema": "folio-library-entry/v1",
  "id": "10665-69096",
  "blocks": [
    {
      "id": "library/10665-69096/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 3,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Pre-qualification of single-use injection devices \nunder the PQS system: A guideline for \nmanufacturers \n \n \n \n \n \n \n \n \n \n \nJune 2005 \n \n \n \n \n \n \n \n \n \n \n \nTable of contents  \nGlossary .........................................................................................................................3 \n2.0 \nBackground....................................................................................................4 \n3.0 \nProcedural guide ............................................................................................4 \n3.1 \nWhat is the PQS system? .........................",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The title page and table of contents of WHO's June 2005 guideline for manufacturers on pre-qualification of single-use injection devices under the PQS (Performance, Quality, Safety) system.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Glossary",
      "pageStart": 3,
      "pageEnd": 4,
      "target": "../sections/sec-000-glossary.md",
      "narrative": null,
      "content": "AD \nAuto-disable (syringe) \nATT \nAccess to Technologies (WHO team of Immunization, Vaccines & \nBiologicals Department) \nEU \nEuropean Union \nEXW \nEx Works (Incoterm) \nGHTF \nGlobal Harmonization Task Force \nGMP \nGood Manufacturing Practices \nIAPSO \nInter-Agency Procurement Services Office (UN agency) \nISO \nInternational Standards Organization \nPIS \nProduct Information Sheets \nPQS \nPerformance, Quality, Safety \nQA \nQuality Assurance \nRPF \nReuse-Prevention Feature \nUN \nUnited Nations \nUNFPA \nUnited Nations Population Fund \nUNICEF \nUnited Nations Children's Fund \nWHO \nWorld Health Organization \nRef",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A glossary of acronyms used in the PQS guideline, such as AD syringe, GHTF, GMP and ISO, followed by the start of the introduction. The introduction explains that the guideline tells manufacturers how to apply to WHO for pre-qualification of single-use injection devices and how to keep or lose that status.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-001-20-background.md",
      "narrative": null,
      "content": "In order to achieve effective infection control for intradermal, subcutaneous and \nintramuscular needle injections, WHO recommends the use of single-use injection \ndevices. Single-use injection devices include single-use syringes used in conjunction \nwith single-use needles, auto-disable (AD) syringes originally designed specifically \nfor immunization, and syringes with a reuse-prevention feature for general purpose. In \nsupport of these recommendations, UNFPA, UNICEF and WHO have stated that, by \nthe end of the year 2003, all countries should only use auto-disable (AD) syringes for \nimmunizat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why WHO recommends single-use injection devices, including auto-disable syringes, for infection control, and recalls the joint UNFPA, UNICEF and WHO statement that only auto-disable syringes should be used for immunization from 2003. It describes the roles of UN agencies and the medical device industry in securing a reliable supply.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Procedural guide",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-002-30-procedural-guide.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What is the PQS system?",
      "pageStart": 4,
      "pageEnd": 5,
      "target": "../sections/sec-003-31-what-is-the-pqs-system.md",
      "narrative": null,
      "content": "What is the PQS system? \nSince 1979 WHO, in collaboration with UNICEF Supply Division, have developed \nand maintained a series of performance specifications and test procedures for \n \n1  World Health Organization. WHO-UNICEF-UNFPA Joint statement on the use of auto-disable syringes \nin immunization services, 1999. WHO document WHO/V&B/99.25. Available from URL: \nhttp://www.who.int/vaccines-documents/DocsPDF99/www9948.pdf \n \nPre-qualification of single-use injection devices under the PQS system: A guideline for manufacturers launched 30 June 2005      5 of 23",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the PQS system's origins in the WHO/UNICEF Product Information Sheets, used since 1979 to specify and test immunization equipment. It explains that conforming products will be listed as pre-qualified in an online database and catalogue.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Transitional arrangements for syringes for fixed dose im",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-004-32-transitional-arrangements-for-syringes-for-fi.md",
      "narrative": null,
      "content": "Transitional arrangements for syringes for fixed dose immunization and \nsyringes with a reuse prevention feature \nBy the 30 June 2005 single-use injection devices previously listed in the PIS will, in \nprinciple, no longer be procured by United Nations agencies unless the new pre-\nqualification procedure, described in this document, has been completed. Under the \nnew procedure, auto-disable (AD) syringes for fixed dose immunization shall comply \nto ISO standard 7886 - part 3, (issued 1 march 2005). Syringes with a reuse \nprevention feature shall comply with ISO-DIS 7886- part 4 (ISO/TC 84/SC 1",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains transitional arrangements: from 30 June 2005 UN agencies will in principle buy only devices pre-qualified under the new procedure, with auto-disable and reuse-prevention syringes required to meet the relevant ISO 7886 standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pre-qualification of syringes for general purpose use",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-005-33-pre-qualification-of-syringes-for-general-pur.md",
      "narrative": null,
      "content": "Pre-qualification of syringes for general purpose use \nIn the first stage of implementation of the PQS only AD syringes for fixed dose \nimmunization and syringes with a reuse-prevention feature will be prequalified under \nthe PQS system. The PQS Steering Group will, in consultation with partners and \nindustry consider the prequalification of therapeutic single-use devices  and insulin \ninjection devices in July 2006 (one year from the date of PQS for injection devices \nintroduction).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that only auto-disable and reuse-prevention syringes will be pre-qualified at first, with therapeutic and insulin devices to be considered in July 2006.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What does PQS pre-qualification mean?",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-006-34-what-does-pqs-pre-qualification-mean.md",
      "narrative": null,
      "content": "What does PQS pre-qualification mean? \nAs noted in paragraph 3.2, injection devices currently listed under the PIS system \nwill, in principle, not longer be purchased by UN procurement agencies after 30 June \n2005, unless they have been pre-qualified under the PQS system.   \n \n2 The 2000 edition of the  Product information Sheets can be downloaded from the WHO website at: \nwww.who.int/vaccines-documents/DocsPDF00/www518.pdf  and new items added since this \npublication are available at http://www.who.int/vaccines-access/vacman/pis/new%20sheets%20intro.htm\n \nPre-qualification of single-use injec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains what pre-qualification means: it shows a device is technically suitable for UN procurement but does not guarantee purchase. Purchasers may add their own specifications, which must not conflict with ISO standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What products are eligible for pre-qualification?",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/sec-007-35-what-products-are-eligible-for-pre-qualificat.md",
      "narrative": null,
      "content": "What products are eligible for pre-qualification? \nDevices that conform to one of the two categories described in this section are \npotentially eligible for pre-qualification.  Compliance with one of the two listed ISO \nstandards is mandatory. Devices that only conform to national or regional standards \nare not eligible even if they do comply with the licensing and/or quality system \nstandards set out in section 3.6.  These are the three categories: \nCategory 1: Syringes for therapeutic use: \nSyringes for general purpose use with a reuse-prevention feature must satisfy the \nrequirements of ISO",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines which syringes are eligible for pre-qualification, requiring compliance with specific ISO standards for therapeutic, fixed-dose immunization and insulin syringes. It notes that needles are not yet covered as a separate category.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What are the minimum licensing requirements?",
      "pageStart": 6,
      "pageEnd": 7,
      "target": "../sections/sec-008-36-what-are-the-minimum-licensing-requirements.md",
      "narrative": null,
      "content": "What are the minimum licensing requirements? \nIf a device is licensed in the territory of one of the founding members of the Global \nHarmonization Task Force (GHTF)3, it meets the minimum quality criteria required \nunder the PQS pre-qualification procedure (Option 1 below). If the device is not \n \n3 The founding members of the GHTF are Australia, Canada, the European Union, Japan and the \nUnited States. \nPre-qualification of single-use injection devices under the PQS system: A guideline for manufacturers launched 30 June 2005      7 of 23 \n \n \n \nlicensed, you must be able to demonstrate to us",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out minimum licensing requirements: devices licensed in a founding member of the Global Harmonization Task Force meet the quality criteria, while others must show conformity with listed quality system standards. Evidence must come from an accredited certification body as certified copies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "How do I apply for pre-qualification?",
      "pageStart": 7,
      "pageEnd": 8,
      "target": "../sections/sec-009-37-how-do-i-apply-for-pre-qualification.md",
      "narrative": null,
      "content": "How do I apply for pre-qualification? \nYou should send an introductory letter, by airmail, surface mail or courier service, to \nthe PQS Secretariat at WHO, Geneva, giving the following information:  \n                                                 \n4 New, proposed legislation. \nPre-qualification of single-use injection devices under the PQS system: A guideline for manufacturers launched 30 June 2005      8 of 23 \n \n \n \n• describe the devices that you have to offer and give the relevant device category \nfor each product – see 3.5; \n• list the standards to which each device conforms and briefly",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how to apply for pre-qualification by sending an introductory letter to the PQS Secretariat describing devices, standards and licensing, with 20 samples per device and site. WHO then either invites a formal application or advises that a device is unsuitable.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1 – Licensing requirements in the five GHTF founding member countries",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table shows, for each of the five Global Harmonization Task Force (GHTF) founding member countries/areas (Australia, Canada, European Union, Japan, United States), the marketing permit or condition required for a medical device.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-69096/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2 - Acceptable quality system standards in the five GHTF founding member countries",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "For each of the five GHTF founding member countries/areas, the table lists the acceptable quality system standards for medical devices and the body that certifies compliance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "How do I prepare a product dossier?",
      "pageStart": 8,
      "pageEnd": 10,
      "target": "../sections/sec-010-38-how-do-i-prepare-a-product-dossier.md",
      "narrative": null,
      "content": "How do I prepare a product dossier? \nYou must submit a separate and complete product dossier for each type of device that \nyou have offered and which we have accepted as being suitable for evaluation.  One \ndossier is required for each volume of syringe (for example, if you submit 1 ml, 2 ml \nand 5 ml syringes we will require three dossiers).   \nIf you are offering a syringe that is manufactured at more than one manufacturing site \nwe will require a separate dossier for each named site. Alternatively you may specify \nthat the syringe will be supplied from one named manufacturing site only.  \nW",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how to prepare a product dossier, requiring a separate dossier for each device type, syringe volume and manufacturing site. It lists the required contents and the address for submission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "How much will I pay?",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/sec-011-39-how-much-will-i-pay.md",
      "narrative": null,
      "content": "How much will I pay? \nWe will charge you on a cost recovery basis for the initial evaluation of your dossier.  \nIf your device is pre-qualified you will also be required to pay an annual re-evaluation \nfee as described in 3.11.2. The current fee scale, which will remain fixed until 31 \nDecember 2005, is shown in Table 3. (WHO will review the fee scale at the end of \n2005). \nTable 3 - Cost recovery fees to be paid to WHO (2005) \nStep \nFee to be paid to WHO \nDossier examination fee \nUS$ 1,000 \nAnnual re-evaluation fee \nUS$ 700 \nNote that these fees will be charged for each and every device you s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out cost-recovery fees for 2005: US$ 1000 for dossier examination and US$ 700 for each annual re-evaluation, charged per device.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The dossier evaluation process",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/sec-012-310-the-dossier-evaluation-process.md",
      "narrative": null,
      "content": "The dossier evaluation process \nWe will review the contents of your dossier. If anything is missing we will contact \nyou in writing giving you a period of one month to provide the missing information, \ndossier fee or samples.  If you fail to respond by the end of this period of grace we \nwill return your dossier; the dossier examination fee will not be refunded.  In addition \nwe will not evaluate your dossier until the dossier fee has been paid in full. \nOnce we have a complete dossier and have cleared your Dossier Examination Fee, we \nwill evaluate the information and samples you have supplie",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the dossier evaluation process, including a one-month grace period for missing items, possible use of independent evaluators under confidentiality, and acceptance of ISO-compliant devices without further testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evaluation results and the approval process",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-013-311-evaluation-results-and-the-approval-process.md",
      "narrative": null,
      "content": "Evaluation results and the approval process \nThe PQS Secretariat will monitor the evaluation process and will endeavour to \nprocess applications as rapidly as resources allow; it will receive and review the \nevaluation results.  The PQS Steering Group makes all final decisions on pre-\nqualification. WHO commit to a time limit of six weeks for the process from receipt \nof a complete dossier. The clock will stop if a dossier submission is incomplete, and \nnot restart until the missing documents are received.   \nIf the results of the evaluation are satisfactory we will write to tell you that your",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how evaluation results are reviewed and decided by the PQS Steering Group within six weeks of a complete dossier, and how manufacturers are told of approval or rejection, with decisions final.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3 - Cost recovery fees to be paid to WHO (2005)",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "The table lists the two cost-recovery fees that manufacturers pay to WHO for pre-qualification of injection devices in 2005: the dossier examination fee and the annual re-evaluation fee.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maintaining pre-qualified status",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-014-312-maintaining-pre-qualified-status.md",
      "narrative": null,
      "content": "Maintaining pre-qualified status \nThe performance of your product and of your company will be kept under continual \nreview through the formal PQS review procedure and throughout the procurement \nprocess at the various UN procurement agencies.   \nIt is essential that you keep us fully informed about any significant change you make \nto the specifications of the product, to the manufacturing process or to the \nmanufacturing site.  If you do not do so, your device may loose its pre-qualified status \n– see section 3.12.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that pre-qualified products are kept under continual review and that manufacturers must report significant changes to product, process or site or risk losing their status.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The extra-ordinary PQS review process",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-015-3121-the-extra-ordinary-pqs-review-process.md",
      "narrative": null,
      "content": "If serious problems arise with the product, leading to vigilance reporting, we reserve \nthe right to re-evaluate your pre-qualification status at any time.  A serious problem is \nan adverse event, device failure or other circumstance requiring immediate action. \nGenerally, we will tell you about the problem and ask you to resolve it by an agreed \ndate.  However, if the problem is severe, we may suspend your pre-qualification status \nuntil it is resolved.  Under some circumstances – for example bankruptcy or \nreceivership – we will withdraw your pre-qualification status entirely.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes extraordinary reviews when serious problems such as adverse events or device failures arise, which may lead to suspension or withdrawal of pre-qualification.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The annual PQS review process",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-016-3122-the-annual-pqs-review-process.md",
      "narrative": null,
      "content": "All PQS pre-qualified injection devices will be reviewed once a year at a single fixed \ntime, that will be communicated to you at the time prequalification is granted, against \na standard checklist based on Annex 4.3. \nThe annual review process will consider all relevant aspects of your device, including \nthose referred to in Section 3.12.  If we have previously highlighted problems which \nyou need to resolve by an agreed date, you must keep us informed about your \nprogress. \nAt least one month in advance, we will remind you of the date of the review and you \nmust ensure that we receive the an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the annual review of pre-qualified devices against a standard checklist, with manufacturers required to pay the re-evaluation fee and submit renewed documents on time. Results are communicated only if problems are found or status changes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Loosing pre-qualified status",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-017-313-loosing-pre-qualified-status.md",
      "narrative": null,
      "content": "Loosing pre-qualified status \nThere are several ways in which you could loose your status as a pre-qualified \nmanufacturer. These include, but are not confined to, the following: \n• if you change the manufacturing site with or without notifying us of your intention \nto do so (Annex 5.2, clause 8); \n• if you change the manufacturing process in an unacceptable way (one that \nnegatively effects the performance of the device) with or without notifying us of \nyour intention to do so (as defined in Annex 5.2, clause 8); \n• if you change the device specification in an unacceptable way (Annex 5.2, cla",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the ways a manufacturer can lose pre-qualified status, such as unapproved changes to site, process or specification, poor quality reports from UN agencies, failure to report adverse events or renew licences, and bankruptcy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Checklists",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-018-40-checklists.md",
      "narrative": null,
      "content": "This section provides you with three checklists designed to ensure that you send us all \nthe information that we require at each of the stages specified.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces three checklists to help manufacturers submit the information needed at each stage of pre-qualification.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preliminary application checklist",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-019-41-preliminary-application-checklist.md",
      "narrative": null,
      "content": "Preliminary application checklist \nRefer to Section 3.7 - Have you included the following? \n1. A covering letter. \n \n2. A description of each device that you wish to offer for evaluation. \n \n3. Brief details of each of your manufacturing sites. \n \n4. Confirmation of the production capacity of each of your manufacturing sites. \n \n5. A list of the standards to which each device conforms. \n \n6. A brief description of the licensing situation for each device. \n \n7. Twenty clearly labelled samples of each device. If the device is made at more than \none site, provide samples from each manufactu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A checklist for the preliminary application, covering the covering letter, device descriptions, site details, standards, licensing and samples.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Dossier submission checklist",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-020-42-dossier-submission-checklist.md",
      "narrative": null,
      "content": "Dossier submission checklist \nRefer to Section 3.8 - Have you included the following items for each device and \nfor each manufacturing site? \n1. A covering letter. \n \n2. A countersigned copy of the letter of invitation received from WHO \n \n3. The correct Dossier Examination Fee, in US dollars. \n \n4. Completed Product Summary Sheet Questionnaire supported by the following \nmaterial: \n \n• \nConfirmation that you are the Legal Manufacturer of the device.  \n \n• \nGeneral information about the manufacturer, including name and address.  \n \n• \nConfirmation of the brand name of the device. \n \n•",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A checklist for dossier submission, covering the invitation letter, dossier fee, product summary questionnaire and supporting evidence such as regulatory approvals and certificates, with one dossier per device and site.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annual review checklist",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-021-43-annual-review-checklist.md",
      "narrative": null,
      "content": "Annual review checklist \nRefer to Section 3.12.2 - Have you included the following items for each pre-\nqualified device and for each manufacturing site? \n1. A covering letter specifying the device to which the dossier refers. \n \n2. The annual re-evaluation fee in US dollars. \n \n3. Certified photocopy of your annual license renewal(s) if the current license(s) is/are \ndue to expire before the review meeting.  \n \n4. Certified photocopy of any additional license(s) that have been issued by a GHTF \nfounding member since you made your last submission. \n \n5. Certified photocopies of all other ti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A checklist for the annual review, covering the re-evaluation fee, renewed licences and certificates and details of changes to sites, processes or specifications.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexes",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-022-50-annexes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5.1 - Definitions",
      "pageStart": 16,
      "pageEnd": 18,
      "target": "../sections/sec-023-annex-51---definitions.md",
      "narrative": null,
      "content": "The following definitions apply to this document: \nAdverse event \nAn incident resulting in permanent impairment, \nhospitalization, congenital malformation, injury or death to \npatients or users of a single-use injection device. \nCertification Body \nA Certification Body is a government department or agency or \na third party organization that provides services for conformity \nassessment following completion of an independent \nassessment verification and qualification process.  In this \ndocument the term is taken to include Notified Body. \nCertified copy \nWherever a certified copy or certified ph",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5.1 giving definitions used in the PQS guideline, such as adverse event, certification body, certified copy and device, with some definitions derived from EU directives and ISO standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5.2 – Standard Terms and Conditions",
      "pageStart": 18,
      "pageEnd": 20,
      "target": "../sections/sec-024-annex-52-standard-terms-and-conditions.md",
      "narrative": null,
      "content": "The Terms and Conditions and Definitions set out below will apply to all \nmanufacturers of PQS pre-qualified injection devices.  You should familiarize \nyourself with this document and ensure that you comply fully with the on-going \nreporting requirements set out therein.  Failure to do so may result in the suspension \nor withdrawal of your pre-qualification status. \nTERMS AND CONDITIONS FOR THE PRE-QUALIFICATION OF SINGLE-USE \nINJECTION DEVICES \n1. Examination of dossier: The Product Dossier will be screened by WHO for completeness prior to \nthe evaluation of the dossier. The dossier can be r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5.2 setting out the standard terms and conditions for pre-qualification of single-use injection devices, which all manufacturers must follow. Clauses cover dossier screening, non-refundable fees, ongoing reporting of changes and adverse events, and grounds for suspension or withdrawal. Definitions of packaging terms such as unit container close the annex.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5.3 – Product Summary Sheet Questionnaire and instruct",
      "pageStart": 20,
      "pageEnd": 22,
      "target": "../sections/sec-025-annex-53-product-summary-sheet-questionnaire-and.md",
      "narrative": null,
      "content": "Information item \nINJECTION DEVICE PRODUCT SUMMARY SHEET (Complete one questionnaire per product and per manufacturing site – see note 1)  \n1 \n  \nDevice description \n \n2 \n \nBrand name \n \nRemarks \n3 \n \nVendor status  \n  Manufacturer     Wholesaler    Distributor     Other (specify)  \n \n \n \n \nName \nAddress \nPhone and Fax \nContact person for \nquality assurance \nWeb-site, e-mail  \n4 \n \nVendor  \n \n \n \n \n \n \nManufacturer  \n \n \n \n \n \n5 \n \nManufacturing Site \n \n \n \n \n \n6 \n \nParent company (if any)  \n \n \n \n \n \nRegulatory authority (check all applicable) \nNumber \nDevice name as submitted to a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5.3, the product summary sheet questionnaire to be completed for each product and site, with instructions. It asks for device and vendor details, regulatory licences in GHTF countries, quality system certificates, test certificates and post-market surveillance reports.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-026-60-references.md",
      "narrative": null,
      "content": "ISO standards and WHO performance specifications: \n1. ISO 7864:1993   Sterile hypodermic needles for single use.  \n2. ISO 7886-1:1993 Sterile hypodermic syringes for single use - Part 1: Syringes for \nmanual use.  \n3. ISO 8537:1991   Sterile single-use syringes, with or without needle, for insulin. \n4. ISO 7886-3: Sterile hypodermic syringes for single use – Part 3: Auto-disable \nsyringes for fixed dose immunization  \n5. ISO DIS 7886-4: Sterile hypodermic syringes for single use – Part 4: Syringes \nwith reuse prevention feature (draft standard, in preparation). \n \nOther references: \n1. WHO. A",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of references for the PQS guideline, citing ISO standards for needles and syringes and WHO documents on injection safety and the Product Information Sheets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69096/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REVISION HISTORY FORM",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-027-revision-history-form.md",
      "narrative": null,
      "content": "(Form number: FCH/IVB /ATT/GEN/F002) \n \n \nSOP Number \n \nDate of original version: \n \n \nREVISIONS \nDate \nReason  \nAuthorized by (Signature \nand Name)",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank revision history form for the PQS guideline, with fields for dates, reasons and authorization.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
